Vigil Neuroscience to Present at 2022 Jefferies Global Healthcare Conference
Vigil Neuroscience, Inc. (Nasdaq: VIGL) has announced that CEO Ivana Magovčević-Liebisch, Ph.D., J.D., will speak at the 2022 Jefferies Global Healthcare Conference on June 8, 2022, at 2:00 p.m. ET in New York City.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vigil Neuroscience, Inc. (Nasdaq: VIGL) has announced that CEO Ivana Magovčević-Liebisch, Ph.D., J.D., will speak at the 2022 Jefferies Global Healthcare Conference on June 8, 2022, at 2:00 p.m. ET in New York City. The event will focus on the company's commitment to leveraging microglia to develop therapies for neurodegenerative diseases. A live webcast of the discussion can be accessed through the 'Investors' section of their website, with an archived replay available for 90 days post-event.
Details
News Market Reaction – VIGL
The recorded move for VIGL in the trading session of this news was +1.72%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch Ph.D., J.D., President and Chief Executive Officer of Vigil, will participate in a fireside chat at the 2022 Jefferies Global Healthcare Conference on Wednesday, June 8, 2022 at 2:00 p.m. ET in New York, New York.
To access a live webcast of this presentation, please visit “Events & Presentations” in the “Investors” section of the Vigil website at www.vigilneuro.com. An archived replay will be available there for approximately 90 days following the presentation.
About Vigil Neuroscience
Vigil Neuroscience is a microglia-focused therapeutics company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in our efforts to develop precision-based therapies to improve the lives of patients and their families.
Internet Posting of Information
Vigil Neuroscience routinely posts information that may be important to investors in the 'Investors' section of its website at https://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.